Fifteen patients presenting with mosaic or non-mosaic karyotypes containing a distamycin-DAPI negative de novo or familial supernumerary marker chromosome were studied with non-isotopic in situ hybridisation using a library of alphoid centromere specific and satellite II/HI probes. The in situ hybridisation studies showed that seven markers were derived from satellited autosomes (three chromosome 13/21, two chromosome 14, two chromosome 22), six from non-satellited autosomes (two chromosome 4, one chromosome 12, one chromosome 16, two chromosome 19), and one from the Y chromosome. One non-mosaic marker was negative for all the alphoid and satellite II/III probes used.
Supernumerary marker chromosomes are found in approximately 2-0/1000 pregnancies studied for prenatal diagnosis' and in 0-3/1000 newborns.2 The frequency of de novo markers increases with maternal age,3 thus accounting for their high incidence among amniocentesis specimens, most of which are referred for this reason. By excluding patients presenting with cytogenetically definable markers such as i(12p) and i(18p) (see Discussion), a recent multicentre study4 has calculated that the incidence of de novo supernumerary markers not identifiable using standard cytogenetic techniques is 1/2500 amniocenteses with satellited and non-satellited markers occurring with approximately equal frequencies.
The phenotypic risks, both intellectual and physical, conferred by the presence of a supernumerary marker have always been difficult to predict owing to the paucity of long term clinical follow up data from such cases. As a result, published risk estimates are given with large margins of error. ' 4 This dilemma is at its most acute when a de novo marker is found prenatally.
A recent study by Warburton4 on a series of 377 353 amniocenteses carried out in the United States and Canada over a 10 year period calculated the risk of an abnormal phenotypic outcome in cases of de novo markers to be approximately 13% and, unlike previous studies,' found no significant difference in the risk conferred by a satellited compared with a non-satellited marker chromosome.
These estimates, however, do not take into account the chromosomal origin of the marker which until recently has been impossible to determine. An exception has been those markers with distamycin-DAPI staining properties by which they are assumed to be derived from chromosome 15. The majority of de novo duplicated distamycin-DAPI staining markers formed from regions including 15pter-.ql2 are associated with mental impairment varying from mild to very severe.5-
The isolation and cloning of centromere specific alphoid sequences,89 together with the development of non-isotopic in situ hybridisation techniques, have made it possible to identify the chromosomal origin of supernumerary marker chromosomes rapidly and systematically. The first reports used probes isolated from the alphoid sequences of the X and Y chromosomes to determine the origin of marker chromosomes in patients with Turner's syndrome."0'2 More recently, studies using autosomal centromere specific probes have identified the chromosomal origin of 13 small ring chromosomes.3 14 We have studied 15 supernumerary marker chromosomes, both familial and de novo, and have determined the chromosomal origin of 14. The phenotypes of 12 of the 15 patients are described in the light of the chromosomal origin of the markers.
Materials and methods
Non-isotopic in situ hybridisation was performed on conventional cytogenetic preparations, usually within 48 hours of making the slides. The in situ hybridisation method used is described in detail elsewhere.'5 Briefly, biotinylated probe DNA (Biotin-16-dUTP, Boehringer Mannheim) was used at a final concentration of 05 to 2 ng DNA/Ill of hybridisation mixture (50% formamide with 10% w/v dextran sulphate, 2 x SSC, and 1/20 vol of sonicated carrier herring sperm DNA). Hybridisation was carried out ovemight at 42 to 45'C and after stringent washing (usually 0-2 x SSC/50% formamide at 37'C for 40 minutes) the sites of hybridisation were detected using either an indirect immunoperoxidase staining method, or fluorescent in situ hybridisation (FISH) following the protocol of Kievits et al. '6 The library of probes used is listed in table 1, from which it can be seen that all centromeres could be individually identified with the exception of 5 and 19, and 13 and 21. In each experiment, the labelling of the normal homologues acted as an internal control and the marker was scored positive for a probe only if Amniocentesis on a 39 year old woman showed a mosaic karyotype with a small ( < 22) marker in 42% of amniocytes examined. The mar(Y) was ring like in appearance and gave two distinct signals with both the DYZ3 (centromere) and DYZ5 (Yp heterochromatin) probes. The pregnancy was terminated and at necropsy the fetus was found to be a hermaphrodite with a short penis, no uterus, and with an ovary on the left side and a testis on the right.
CASE 15: 47,XX, + MAR(?ORIGIN) DE NOVO
Amniocentesis on a 36 year old woman showed the presence of a small (< 22) marker in all cells examined. In situ hybridisation was performed with all the probes in the library but no signal was seen from the marker in the 10 cells examined after each hybridisation. The pregnancy was terminated and the necropsy report indicated an apparently normal fetus with no major congenital abnormalities.
Discussion
The phenotypic consequences of a supernumerary marker chromosome remain difficult to evaluate despite a number of conventional cytogenetic staining methods. Some markers, for example i(12p) and i(18p), can (14) in case 7 of this study may also be maternal in origin resulting in an excess of maternally derived genes for the pericentric region of chromosome 14. Marker chromosomes may, therefore, cause an abnormal phenotype not only by dosage effects, but also because of chromosome specific imprinting resulting in an imbalance between the normal ratio of maternal and patemal genes. Indeed, such an effect is well established in some patients with markers derived from chromosome 15 who have the Prader-Willi syndrome. 7 Six of the remaining 10 cases ascertained through prenatal diagnosis had normal phenotypes. In case 3, the chromosomal assignment of the marker(12) was made postnatally. With the known association of Pallister-Killian syndrome and the tetrasomy 12p marker chromosome,.7 it is difficult to assess retrospectively how the chromosomal assignment of the marker (12) would have affected the risk estimates if the in situ results had been known prenatally. The marker (12) in this case suggests that triplication (or quadruplication) of the pericentromeric region of chromosome 12 alone is not sufficient to produce the Pallister-Killian phenotype.
It is interesting to note that cases 12 and 13, both of which had karyotypes with non-mosaic bisatellited and dicentric marker (22) 
